The combined Bz + PTX therapy not only reinforced the role of miR-146a-5p targeting IL1R1 (Interleukin-1 receptor 1), IL10 (Interleukin 10), CRP (C-reactive protein) and CXCL8 (CXC-chemokine 8 ligand), but also brought to light the involvement of miR-21-5p, miR-132-3p, and miR-148a-3p in modulating genes related to ‘Neurodegenerative diseases’ and ‘Central nervous system inflammation’ (S7 Fig). The gene discussed is IL1R1; the disease is encephalomyelitis.